Brief: Merck CEO sees Prometheus drug as multi-billion dollar opportunity

Prometheus Biosciences

16/04/2023 18:25

April 16 (Reuters) - Merck & Co Inc  MRK.N :
    * Merck CEO sees Prometheus' ulcerative colitis/Crohn's drug
PRA023 as "a multibillion-dollar opportunity"
    * Merck CEO says can launch phase 3 ulcerative colitis study
for
PRA023 in Q4 '23 OR Q1 '24 if Prometheus deal closes in Q3 '23


Further company coverage:  MRK.N 

 (Reporting By Michael Erman)
 ((Michael.Erman@thomsonreuters.com;))